The Expo 2020 Dubai joined Hands with Terminus Group at the Pujiang Innovation Forum, a showcase of Cutting-Edge Innovative Technologies
SHANGHAI, CHINA / ACCESSWIRE / June 11, 2021 / The Expo 2020 Dubai and its…
SHANGHAI, CHINA / ACCESSWIRE / June 11, 2021 / The Expo 2020 Dubai and its…
VANCOUVER, BC / ACCESSWIRE / June 11, 2021 / Pure Extraction Corp. (“Purx” or the…
NEW YORK, NY / ACCESSWIRE / June 11, 2021 /AdvanceTC Limited (NSX:A88, OTCQB:ATCLF) The global…
The Long Island-area restaurant owner and serial entrepreneur sat down with an online journalist to…
The serial entrepreneur and president and CEO of NEX-XOS Worldwide sat down to discuss the…
The Texas-based all-purpose smart home and security firm calls attention to the unique and inspirational…
SINGAPORE, SINGAPORE / ACCESSWIRE / June 11, 2021 / Jadestone Energy plc (the ‘Company‘ or…
Low-latency, high-availability connections at key centers of data exchange power new possibilities of scale for…
Orphazyme A/SCompany announcement        No. 15/2021Company Registration No. 32266355 Copenhagen – June 11, 2021 – Orphazyme A/S…
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies…
Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual…
     New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational…
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults…
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when…
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises…
– Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in…
Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus…
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies…
Four-year follow-up analysis from the phase III CLL14 study showed progression-free survival rate of 74.0%…
Data from JEWELFISH, the first trial in a diverse population aged 1 to 60 years…